Navigation Links
Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
Date:12/6/2013

LONDON, Dec. 6, 2013 /PRNewswire/ -- Edison Investment Research's report, An intriguing PROSPECT, examines the long-term investment case for Bavarian Nordic, which rests on key value driver Prostvac, its Phase III prostate cancer vaccine.

Prostvac is well positioned to succeed where Provenge, the only approved prostate cancer vaccine, has so far failed. Final data from the pivotal Phase III PROSPECT trial are not due until 2016 but with enrolment on track to complete in H114, there is potential for interim analyses in 2015. PROSPECT data, coupled with read out of two Phase II Xtandi combination studies and an impressive 8.5-month overall survival benefit shown in the Phase II monotherapy trial, should help Bavarian Nordic secure a partner.

Its smallpox vaccine Imvamune is currently the revenue driver, with recurring revenues generated though supplies to the US government. Further orders are expected and new clinical data from 2016 should strengthen its market position, helping Bavarian Nordic towards sustainable and growing profitability.

Edison's healthcare team values the company at DKK2,965m, with potential for further upside.

For the full report see: www.edisoninvestmentresearch.com/research/company/bavarian-nordic  

About Edison Investment Research The launch of coverage on Bavarian Nordic is part of a programme of research initiations on biotech companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. All reports Edison publishes are available to download free of charge from its website www.edisongroup.com.

Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. For more information please contact:Lala GregorekEdison Investment Research+44 (0)20 3681 2527Robin DavisonEdison Investment Research+44 (0)20 3077 5737healthcare@edisongroup.comAbout Bavarian NordicBavarian Nordic is a Danish biotech focused on developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Its lead products are Prostvac (prostate cancer) and Imvamune (smallpox).


'/>"/>
SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
2. Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
3. Concord Medical Signs MOU with Shanghai New Hongqiao International Medical Center and GE Healthcare to Establish a Medical Imaging Diagnosis Center
4. Ansell Limited To Acquire BarrierSafe Solutions International
5. Archbishop Desmond Tutu Advocates St John International Charity Work on Packed London Visit and Audience with HM The Queen
6. Assurex Health Announces International Expansion through Canadian Partnership with the Centre for Addiction and Mental Health
7. Biotest Pharmaceuticals Honored with the 2013 Greater Miami Chamber of Commerce International Business Leadership Award for "Business Expansion"
8. Edison expands international bio-pharmaceutical presence with launch of coverage of Onconova Therapeutics
9. Philips Honored With Prestigious Respiratory Industry Excellence Award At AARC International Respiratory Congress
10. International Isotopes Inc. Announces Third Quarter And Nine Months 2013 Financial Results
11. New U.S. Patent Issued To Dyadic International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016  It,s time for an upgrade. There are many medical recorders on the ... LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a ... class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... 4, 2016 Valeritas Holdings, Inc. ... alternative public offering (APO). This was accomplished via a ... Inc. and a private placement of approximately 5 million ... share. Under the terms of the reverse ... Holdings, Inc. will trade on the OTC Markets under ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute lymphocytic Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Lymphocytic Leukemia epidemiology, Acute ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... The Spiritual Care Association (SCA) ... their valuable support to patients and their families, and their overall contribution to the ... Spiritual Care Day, SCA has sent “Thank You Chaplain” cards with hand-painted artwork to ...
(Date:5/4/2016)... ... ... A new collaboration will give more researchers access to the largest and ... leader SAS will provide researchers worldwide with data management and analytics tools to explore ... , The DCRI and SAS share the goal of greater transparency and openness in ...
(Date:5/4/2016)... ... ... Washington Wellness Center today announced its tenth anniversary of providing a complete ... as an idea to provide a holistic approach to wellness has now become a ... David Swanekamp, Chiropractic Physician , the wellness center offers a complete range of ...
(Date:5/4/2016)... ... 2016 , ... Dr. Elyson and Dr. Assili, dentist in Northridge , ... tooth removal, a common dental procedure, is performed for many adolescents and young adults ... in risks of complications. By providing wisdom tooth removal surgery at their office, Dr. ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Recognizing that ... launched health brand, Verywell, have tapped David Katz, MD, MPH, president of ... , “Our shared devotion to lifestyle medicine is especially gratifying,” said Katz. “There is ...
Breaking Medicine News(10 mins):